• LAST PRICE
    457.1201
  • TODAY'S CHANGE (%)
    Trending Down-5.0199 (-1.0862%)
  • Bid / Lots
    457.1300/ 2
  • Ask / Lots
    458.0000/ 4
  • Open / Previous Close
    460.0000 / 462.1400
  • Day Range
    Low 457.0000
    High 462.1300
  • 52 Week Range
    Low 341.8500
    High 510.6350
  • Volume
    137,144
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 462.14
TimeVolumeVRTX
09:32 ET8914460.7
09:34 ET2251460
09:36 ET1645460.94
09:39 ET733460.57
09:41 ET1065460
09:43 ET4098460
09:45 ET3276459.505
09:48 ET2530459.21
09:50 ET900460.3
09:52 ET1112460.205
09:54 ET2804460.09
09:57 ET710460.5
09:59 ET1507460.89
10:01 ET2791461.41
10:03 ET1000461.13
10:06 ET250461.26
10:08 ET2640460.35
10:10 ET300460.785
10:12 ET2059461.435
10:14 ET300461.8
10:15 ET5132461.72
10:17 ET500461.71
10:19 ET300461.85
10:21 ET2734461
10:24 ET2347460.25
10:26 ET4328460
10:28 ET100459.975
10:30 ET2029460
10:32 ET894459.54
10:33 ET6928458.965
10:35 ET2867459.03
10:37 ET719459.375
10:39 ET3700459.38
10:42 ET1497458.5
10:44 ET2792457
10:46 ET2398457.55
10:48 ET200457.1201
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVRTX
Vertex Pharmaceuticals Inc
119.3B
-225.8x
+46.35%
United StatesREGN
Regeneron Pharmaceuticals Inc
114.7B
27.2x
+10.93%
United StatesBIIB
Biogen Inc
27.5B
23.3x
-18.14%
United StatesICLR
ICON PLC
24.4B
34.3x
+4.68%
United StatesIQV
IQVIA Holdings Inc
42.2B
29.7x
+46.62%
United StatesMRNA
Moderna Inc
24.3B
-4.0x
---
As of 2024-10-03

Company Information

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Contact Information

Headquarters
50 Northern AvenueBOSTON, MA, United States 02210
Phone
617-341-6393
Fax
---

Executives

Executive Chairman of the Board
Jeffrey Leiden
President, Chief Executive Officer, Director
Reshma Kewalramani
Chief Financial Officer, Executive Vice President
Charles Wagner
Chief Operating Officer, Executive Vice President
Stuart Arbuckle
Executive Vice President - Global Research, Chief Scientific Officer
David Altshuler

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$119.3B
Revenue (TTM)
$10.3B
Shares Outstanding
258.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.40
EPS
$-2.02
Book Value
$68.22
P/E Ratio
-225.8x
Price/Sales (TTM)
11.5
Price/Cash Flow (TTM)
---
Operating Margin
-3.37%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.